This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Fakouhi, T. D. Articles by Cutler, N. R. Search for Related Content PubMed Articles by Fakouhi, T. D. Articles by Cutler, N. R. Social Bookmarking                         What's this?

Evaluation of Cycloserine in the Treatment of Alzheimer's Disease

G.D. Searle Company (Drs. Fakouhi, Herting, Swabb, and Mr. Benes, Ms. Schwartz, and Mr. Hantsburger), Skokie, Illinois, and from California Clinical Trials (Drs. Jhee, Sramek, and Cutler), Beverly Hills, California.

Stanford S. Jhee, PharmD

G.D. Searle Company (Drs. Fakouhi, Herting, Swabb, and Mr. Benes, Ms. Schwartz, and Mr. Hantsburger), Skokie, Illinois, and from California Clinical Trials (Drs. Jhee, Sramek, and Cutler), Beverly Hills, California.

John J. Sramek, PharmD

G.D. Searle Company (Drs. Fakouhi, Herting, Swabb, and Mr. Benes, Ms. Schwartz, and Mr. Hantsburger), Skokie, Illinois, and from California Clinical Trials (Drs. Jhee, Sramek, and Cutler), Beverly Hills, California.

Charles Benes, MA

G.D. Searle Company (Drs. Fakouhi, Herting, Swabb, and Mr. Benes, Ms. Schwartz, and Mr. Hantsburger), Skokie, Illinois, and from California Clinical Trials (Drs. Jhee, Sramek, and Cutler), Beverly Hills, California.

Patricia Schwartz, BA

G.D. Searle Company (Drs. Fakouhi, Herting, Swabb, and Mr. Benes, Ms. Schwartz, and Mr. Hantsburger), Skokie, Illinois, and from California Clinical Trials (Drs. Jhee, Sramek, and Cutler), Beverly Hills, California.

Gary Hantsburger, MS

G.D. Searle Company (Drs. Fakouhi, Herting, Swabb, and Mr. Benes, Ms. Schwartz, and Mr. Hantsburger), Skokie, Illinois, and from California Clinical Trials (Drs. Jhee, Sramek, and Cutler), Beverly Hills, California.

Robert Herting, MD, PhD,

G.D. Searle Company (Drs. Fakouhi, Herting, Swabb, and Mr. Benes, Ms. Schwartz, and Mr. Hantsburger), Skokie, Illinois, and from California Clinical Trials (Drs. Jhee, Sramek, and Cutler), Beverly Hills, California.

Edward A. Swabb, MD, PhD

G.D. Searle Company (Drs. Fakouhi, Herting, Swabb, and Mr. Benes, Ms. Schwartz, and Mr. Hantsburger), Skokie, Illinois, and from California Clinical Trials (Drs. Jhee, Sramek, and Cutler), Beverly Hills, California.

Neal R. Cutler, MD

G.D. Searle Company (Drs. Fakouhi, Herting, Swabb, and Mr. Benes, Ms. Schwartz, and Mr. Hantsburger), Skokie, Illinois, and from California Clinical Trials (Drs. Jhee, Sramek, and Cutler), Beverly Hills, California.

This multicenter study evaluated the efficacy and safety of cycloserine and measured its effects on explicit and implicit memory tests in patients with Alzheimer's disease (AD). Four hundred ten patients with AD, aged 50 years or older, were enrolled in this parallel-group, double-blind, placebo-controlled, randomized trial of 5,15, or 50 mg cycloserine or placebo twice daily, and 403 entered the double-blind treatment phase. Two hundred sixty-five patients completed the entire 26-week treatment phase. There were no baseline differences among the four treatment groups. Cognitive Drug Research (CDR) efficacy assessments showed no differences between active treatments and placebo from baseline to study weeks 2, 6, 14, or 26. Patients receiving 15 mg of cycloserine improved significantly on one section of an implicit memory test. No differences among treatments were observed for any other assessment scales evaluated. The incidence and severity of adverse events were similar across treatment groups. Cycloserine was well tolerated but did not demonstrate consistent evidence of efficacy during the course of therapy. Higher doses may be necessary to achieve efficacy in the AD population and do not appear to be precluded by the adverse event profile seen in this study.

Journal of Geriatric Psychiatry and Neurology, Vol. 8, No. 4, 226-230 (1995)
DOI: 10.1177/089198879500800405


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Wilhelm, U. Buhlmann, D. F. Tolin, S. A. Meunier, G. D. Pearlson, H. E. Reese, P. Cannistraro, M. A. Jenike, and S. L. Rauch Augmentation of Behavior Therapy With D-Cycloserine for Obsessive-Compulsive Disorder Am J Psychiatry, March 1, 2008; 165(3): 335 - 341. [Abstract] [Full Text] [PDF]

				S. G. Hofmann, A. E. Meuret, J. A. J. Smits, N. M. Simon, M. H. Pollack, K. Eisenmenger, M. Shiekh, and M. W. Otto Augmentation of exposure therapy with d-cycloserine for social anxiety disorder. Arch Gen Psychiatry, March 1, 2006; 63(3): 298 - 304. [Abstract] [Full Text] [PDF]